Stoke Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Stoke Therapeutics es Ed Kaye , nombrado en Oct 2017, tiene una permanencia de 7.08 años. compensación anual total es $3.53M, compuesta por 17.7% salario y 82.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.051% de las acciones de la empresa, por valor de $308.64K. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 6.2 años, respectivamente.
Información clave
Ed Kaye
Chief Executive Officer (CEO)
US$3.5m
Compensación total
| Porcentaje del salario del CEO | 17.7% |
| Permanencia del CEO | 7.1yrs |
| Participación del CEO | 0.05% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Nov 08
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Nov 06Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
Compensación vs. Mercado: La compensación total ($USD3.53M) de Ed está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.18M).
Compensación vs. Ingresos: La compensación de Ed ha sido consistente con los resultados de la empresa en el último año.
CEO
Ed Kaye (75 yo)
7.1yrs
Permanencia
US$3,533,210
Compensación
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 7.1yrs | US$3.53m | 0.051% $ 308.6k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.76% $ 4.6m | |
| Chief Medical Officer | 7.1yrs | US$1.65m | 0.0047% $ 28.4k | |
| Co-Founder & Senior VP of Discovery Research | no data | sin datos | sin datos | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Head of Investor Relations | no data | sin datos | sin datos | |
| Corporate Secretary & General Counsel | 3.8yrs | sin datos | 0.0049% $ 29.7k | |
| Chief Communications Officer | 3.8yrs | sin datos | sin datos | |
| Chief Human Resources Officer | 5.1yrs | sin datos | sin datos | |
| Senior VP of Quality & Chief Regulatory Affairs Officer | 5.9yrs | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos |
3.8yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de STOK se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 7.1yrs | US$3.53m | 0.051% $ 308.6k | |
| Co-Founder & Independent Director | 10.4yrs | US$198.33k | 0.76% $ 4.6m | |
| Independent Director | 9.3yrs | US$237.33k | 3.54% $ 21.4m | |
| Independent Director | 9.2yrs | US$198.33k | 0.034% $ 205.5k | |
| Independent Director | 1.2yrs | US$394.03k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$209.33k | 0% $ 0 | |
| Independent Chairman | 6.2yrs | US$211.83k | 0.060% $ 362.8k |
6.2yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de STOK se considera experimentada (6.2 años de antigüedad promedio).